Affymetrix Broadens Technology Deal
with BioMerieux to Cancer Diagnostics
Affymetrix has expanded an existing technology agreement with diagnostics company BioMerieux to include further disease areas, the companies said this week.
Under the agreement, BioMerieux, of Marcy L'Etoile, France, has non-exclusive rights to Affymetrix's GeneChip technology, including future improvements, to develop and market in vitro diagnostics for breast cancer. The company also has the option to broaden this agreement to other cancers.